Investigational drugs in early-stage clinical trials for autism spectrum disorder

References

• Baio, J. Prevalence of autism spectrum disorders–autism and developmental disabilities monitoring network, 14 sites, United States, 2008. MMWR Surveill Summ. 2012 Mar 30;61(3):1–19. PubMed PMID: 22456193; eng
   Google Scholar
• The_Interagency_Autism_Coordinating_Committee. 2010 strategic plan for autism spectrum disorder research. NIH Publication No. 10-7573: Department of Health & Human Services USA; 2010.
   Google Scholar
• IACC Strategic Plan. [ cited 2018 May 14]. Available from: https://iacc.hhs.gov/news/2017/strategic-plan-release.shtml?utm_source=newsletter&utm_medium=email&utm_campaign=october_20172017
   Google Scholar
• Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009 Dec;124(6):1533–1540. PubMed PMID: 19948625; eng.
   PubMed Web of Science ®Google Scholar
• McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002 Aug 1;347(5):314–321. PubMed PMID: 12151468.
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology Autism N. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005 Nov;62(11):1266–1274. 62/11/1266 [pii] PubMed PMID: 16275814; eng.
   PubMed Web of Science ®Google Scholar
• Fung LK, Mahajan R, Nozzolillo A, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics. 2016;137(Supplement 2):S124–S135.
   PubMed Web of Science ®Google Scholar
• LeClerc S, Easley D. Pharmacological therapies for autism spectrum disorder: a review. Pharm Ther. 2015;40(6):389.
   Google Scholar
• Doyle CA, McDougle CJ. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci. 2012;14(3):263.
   PubMedGoogle Scholar
• Wink LK, Plawecki MH, Erickson CA, et al. Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. Expert Opin Emerg Drugs. 2010;15(3):481–494.
   PubMed Web of Science ®Google Scholar
• Reiersen AM, Todd RD. Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment. Expert Rev Neurother. 2008;8(4):657–669.
   PubMedGoogle Scholar
• Williams K, Brignell A, Randall M, et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013 Aug 20;(8):CD004677. pub3. PubMed PMID: 23959778. doi:10.1002/14651858.CD004677.
   PubMed Web of Science ®Google Scholar
• Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. 2008 Oct;17(4):787–801, viii-ix. PubMed PMID: 18775370; PubMed Central PMCID: PMCPMC2566849
   Web of Science ®Google Scholar
• Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003 Oct;2(5):255–267. PubMed PMID: 14606691
   PubMed Web of Science ®Google Scholar
• Nelson SB, Valakh V. Excitatory/Inhibitory balance and circuit homeostasis in autism spectrum disorders. Neuron. 2015 Aug 19;87(4):684–698. PubMed PMID: 26291155; PubMed Central PMCID: PMCPMC4567857.
   PubMed Web of Science ®Google Scholar
• Ma D, Whitehead P, Menold M, et al. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am J Hum Genet. 2005;77(3):377–388.
   PubMed Web of Science ®Google Scholar
• Coghlan S, Horder J, Inkster B, et al. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev. 2012;36(9):2044–2055.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Posey DJ, Stigler KA, et al. Glutamatergic function in autism. In: Heresco-Levy U, editor. Glutamate in neuropsychiatric disorders. Trivandrum, Kerala, India: Research Signpost; 2008. p. 197–212.
   Google Scholar
• Insel TR, O’Brien DJ, Leckman JF. Oxytocin, vasopressin, and autism: is there a connection? Biol Psychiatry. 1999;45(2):145–157.
   PubMed Web of Science ®Google Scholar
• Lukas M, Neumann ID. Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. Behav Brain Res. 2013;251:85–94.
   PubMed Web of Science ®Google Scholar
• Young LJ, Barrett CE. Neuroscience. Can oxytocin treat autism? Science. 2015 Feb 20;347(6224):825–826. PubMed PMID: 25700501; PubMed Central PMCID: PMCPMC4362686.
   PubMed Web of Science ®Google Scholar
• Fernandez M, Mollinedo-Gajate I, Penagarikano O. Neural circuits for social cognition: implications for autism. Neuroscience. 2018 Feb 1;370:148–162. PubMed PMID: 28729065.
   PubMed Web of Science ®Google Scholar
• Green L, Fein D, Modahl C, et al. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry. 2001 Oct 15;50(8):609–613. PubMed PMID: 11690596
   PubMed Web of Science ®Google Scholar
• Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry. 1998 Feb 15;43(4):270–277. PubMed PMID: 9513736
   PubMed Web of Science ®Google Scholar
• Guastella AJ, Kenyon AR, Alvares GA, et al. Intranasal arginine vasopressin enhances the encoding of happy and angry faces in humans. Biol Psychiatry. 2010;67(12):1220–1222.
   PubMed Web of Science ®Google Scholar
• Brunnlieb C, Nave G, Camerer CF, et al. Vasopressin increases human risky cooperative behavior. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2051–2056. PubMed PMID: 26858433; PubMed Central PMCID: PMCPMC4776476. eng.
   PubMed Web of Science ®Google Scholar
• Momeni N, Nordström BM, Horstmann V, et al. Alterations of prolyl endopeptidase activity in the plasma of children with autistic spectrum disorders. BMC Psychiatry. 2005;5(1):27.
   PubMed Web of Science ®Google Scholar
• Boso M, Emanuele E, Politi P, et al. Reduced plasma apelin levels in patients with autistic spectrum disorder. Arch Med Res. 2007;38(1):70–74.
   PubMed Web of Science ®Google Scholar
• Atladóttir HÓ, Pedersen MG, Thorsen P, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics. 2009;124(2):687–694.
   PubMed Web of Science ®Google Scholar
• Careaga M, Van de Water J, Ashwood P. Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics. 2010;7(3):283–292.
   PubMed Web of Science ®Google Scholar
• Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun. 2012;26(3):383–392.
   PubMed Web of Science ®Google Scholar
• Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med. 2011;17(7):389–394.
   PubMed Web of Science ®Google Scholar
• Main PA, Angley MT, Thomas P, et al. Folate and methionine metabolism in autism: a systematic review. Am J Clin Nutr. 2010;91(6):1598–1620.
   PubMed Web of Science ®Google Scholar
• Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA). 2001;65(1):1–7.
   PubMed Web of Science ®Google Scholar
• Johnson S, Hollis C, Kochhar P, et al. Autism spectrum disorders in extremely preterm children. J Pediatr. 2010;156(4):525–531. e2.
   PubMed Web of Science ®Google Scholar
• Limperopoulos C, Bassan H, Sullivan NR, et al. Positive screening for autism in ex-preterm infants: prevalence and risk factors. Pediatrics. 2008;121(4):758–765.
   PubMed Web of Science ®Google Scholar
• Belmonte MK, Allen G, Beckel-Mitchener A, et al. Autism and abnormal development of brain connectivity. J Neurosci. 2004;24(42):9228–9231.
   PubMed Web of Science ®Google Scholar
• Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B. 2006;9(6):485–499.
   PubMed Web of Science ®Google Scholar
• James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. Faseb J. 2009;23(8):2374–2383.
   PubMed Web of Science ®Google Scholar
• Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012;17(4):389.
   PubMed Web of Science ®Google Scholar
• Joshi G, Wozniak J, Faraone SV, et al. A prospective open-label trial of memantine hydrochloride for the treatment of social deficits in intellectually capable adults with autism spectrum disorder. J Clin Psychopharmacol. 2016;36(3):262–271.
   PubMed Web of Science ®Google Scholar
• Aman MG, Findling RL, Hardan AY, et al. Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. J Child Adolesc Psychopharmacol. 2017;27(5):403–412.
   PubMed Web of Science ®Google Scholar
• Urbano M, Okwara L, Manser P, et al. A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. Clin Neuropharmacol. 2014;37(3):69.
   PubMed Web of Science ®Google Scholar
• Urbano M, Okwara L, Manser P, et al. A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders. J Neuropsychiatry Clin Neurosci. 2015;27(2):133–138.
   PubMed Web of Science ®Google Scholar
• Minshawi NF, Wink LK, Shaffer R, et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Mol Autism. 2016;7(1):2.
   PubMed Web of Science ®Google Scholar
• Wink LK, Minshawi NF, Shaffer RC, et al. D-Cycloserine enhances durability of social skills training in autism spectrum disorder. Mol Autism. 2017;8(1):2.
   PubMed Web of Science ®Google Scholar
• Naassila M, Hammoumi S, Legrand E, et al. Mechanism of action of acamprosate. Part I. Characterization of spermidine sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res. 1998;22(4):802–809.
   PubMed Web of Science ®Google Scholar
• Blednov YA, Adron Harris R. Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int J Neuropsychopharmacol. 2008;11(6):775–793.
   PubMed Web of Science ®Google Scholar
• Mann K, Kiefer F, Spanagel R, et al. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res. 2008;32(7):1105–1110.
   PubMed Web of Science ®Google Scholar
• Pierrefiche O, Daoust M, Naassila M. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology. 2004;47(1):35–45.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Early M, Stigler KA, et al. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol. 2011;21(6):565–569.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Wink LK, Early MC, et al. Brief report: pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. J Autism Dev Disord. 2014;44(4):981–987.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–1142.
   PubMed Web of Science ®Google Scholar
• Wink LK, O’Melia AM, Shaffer RC, et al. Intranasal ketamine treatment in an adult with autism spectrum disorder. J Clin Psychiatry. 2014;75(8):835–836.
   PubMed Web of Science ®Google Scholar
• Bradstreet JJ, Sych N, Antonucci N, et al. Efficacy of fetal stem cell transplantation in autism spectrum disorders: an open-labeled pilot study. Cell Transplant. 2014;23(1):S105–S112.
   PubMed Web of Science ®Google Scholar
• Lv Y-T, Zhang Y, Liu M, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med. 2013;11(1):196.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Veenstra-Vanderweele JM, Melmed RD, et al. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2014;44(4):958–964.
   PubMed Web of Science ®Google Scholar
• Veenstra-VanderWeele J, Cook EH, King BH, et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology. 2017;42(7):1390.
   PubMed Web of Science ®Google Scholar
• Dzhala VI, Brumback AC, Staley KJ. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. Ann Neurol. 2008;63(2):222–235.
   PubMed Web of Science ®Google Scholar
• Blaesse P, Airaksinen MS, Rivera C, et al. Cation-chloride cotransporters and neuronal function. Neuron. 2009;61(6):820–838.
   PubMed Web of Science ®Google Scholar
• Hadjikhani N, Johnels JÅ, Lassalle A, et al. Bumetanide for autism: more eye contact, less amygdala activation. Sci Rep. 2018;8(1):3602.
   PubMed Web of Science ®Google Scholar
• Hadjikhani N, Zürcher NR, Rogier O, et al. Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study. Autism. 2015;19(2):149–157.
   PubMed Web of Science ®Google Scholar
• Lemonnier É, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry. 2012;2(12):e202.
   PubMed Web of Science ®Google Scholar
• Du L, Shan L, Wang B, et al. A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism. J Child Adolesc Psychopharmacol. 2015;25(7):585–588.
   PubMed Web of Science ®Google Scholar
• Lemonnier E, Villeneuve N, Sonie S, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry. 2017;7(3):e1056.
   PubMed Web of Science ®Google Scholar
• Hosie AM, Wilkins ME, Da Silva HM, et al. Endogenous neurosteroids regulate GABA A receptors through two discrete transmembrane sites. Nature. 2006;444(7118):486.
   PubMed Web of Science ®Google Scholar
• Kostakis E, Smith C, Jang M-K, et al. The neuroactive steroid pregnenolone sulfate stimulates trafficking of functional NMDA receptors to the cell surface via a non-canonical G-protein and Ca++ dependent mechanism. Mol Pharmacol. 2013;113:085696.
   Google Scholar
• Fung LK, Libove RA, Phillips J, et al. Brief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder. J Autism Dev Disord. 2014;44(11):2971–2977.
   PubMed Web of Science ®Google Scholar
• Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47(6Suppl 4):233S–241S.
   Web of Science ®Google Scholar
• Mantz J, Laudenbach V, Lecharny J-B, et al. Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol. 1994;257(1–2):R7–R8.
   PubMed Web of Science ®Google Scholar
• He Y, Benz A, Fu T, et al. Neuroprotective agent riluzole potentiates postsynaptic GABAA receptor function. Neuropharmacology. 2002;42(2):199–209.
   PubMed Web of Science ®Google Scholar
• Ajram L, Horder J, Mendez M, et al. Shifting brain inhibitory balance and connectivity of the prefrontal cortex of adults with autism spectrum disorder. Transl Psychiatry. 2017;7(5):e1137.
   PubMed Web of Science ®Google Scholar
• Wink LK, Adams R, Horn PS, et al. A randomized placebo-controlled cross-over pilot study of riluzole for drug-refractory irritability in autism spectrum disorder. J Autism Dev Disord. 2018;48(9):3051–3060.
   PubMed Web of Science ®Google Scholar
• Anagnostou E, Soorya L, Brian J, et al. Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth. Brain Res. 2014 Sep;11(1580):188–198. PubMed PMID: 24508578.
   PubMed Web of Science ®Google Scholar
• Tachibana M, Kagitani-Shimono K, Mohri I, et al. Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2013;23(2):123–127.
   PubMed Web of Science ®Google Scholar
• Yatawara C, Einfeld S, Hickie I, et al. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry. 2016;21(9):1225.
   PubMed Web of Science ®Google Scholar
• Guastella AJ, Gray KM, Rinehart NJ, et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry. 2015;56(4):444–452.
   PubMed Web of Science ®Google Scholar
• Dadds MR, MacDonald E, Cauchi A, et al. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord. 2014;44(3):521–531.
   PubMed Web of Science ®Google Scholar
• Parker KJ, Oztan O, Libove RA, et al. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Nat Acad Sci. 2017;114(30):8119–8124.
   PubMed Web of Science ®Google Scholar
• Fukai M, Hirosawa T, Kikuchi M, et al. Oxytocin effects on emotional response to others’ faces via serotonin system in autism: a pilot study. Psychiatry Res Neuroim. 2017;267:45–50.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kuroda M, Kuwabara H, et al. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain. 2015;138(11):3400–3412.
   PubMed Web of Science ®Google Scholar
• Kosaka H, Okamoto Y, Munesue T, et al. Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial. Transl Psychiatry. 2016;6(8):e872.
   PubMed Web of Science ®Google Scholar
• Umbricht D, Del Valle Rubido M, Hollander E, et al. A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology. 2017;42(9):1914.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): national library of medicine (US). 2000 Feb 29 -. Identifier NCT01962870, The Role of Vasopressin in the Social Deficits of Autism; 2013 Oct 14 [cited 2019 Feb 6]; 7. Available from: https://clinicaltrials.gov/ct2/show/NCT01962870?term=vasopressin&cond=Autism&rank=1.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): national library of medicine (US). 2000 Feb 29 -. Identifier NCT03204786, Intranasal Vasopressin Treatment in Children With Autism; 2017 Jul 2 [cited 2019 Feb 6]; 7. Available from: https://clinicaltrials.gov/ct2/show/NCT03204786?term=vasopressin&cond=Autism&draw=1&rank=2.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): national Library of Medicine (US). 2000 Feb 29 -. Identifier NCT01093768, Brain Imaging Study of Adults With Autism Spectrum Disorders; 2010 Mar 26 [cited 2019 Feb 6]; 7. Available from: https://clinicaltrials.gov/ct2/show/NCT01093768?term=vasopressin&cond=Autism&draw=1&rank=3.
   Google Scholar
• De Miguel PM, Fuentes-Julian S, Blazquez-Martinez A, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012;12(5):574–591.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815–1822.
   PubMed Web of Science ®Google Scholar
• Park D-H, Borlongan CV, Willing AE, et al. Human umbilical cord blood cell grafts for brain ischemia. Cell Transplant. 2009;18(9):985–998.
   PubMed Web of Science ®Google Scholar
• Burns TC, Verfaillie CM, Low WC. Stem cells for ischemic brain injury: a critical review. J Comp Neurol. 2009;515(1):125–144.
   PubMed Web of Science ®Google Scholar
• Li Q, Chen C, Wang D, et al. Transplantation of umbilical cord blood mononuclear cells increases levels of nerve growth factor in the cerebrospinal fluid of patients with autism. Genet Mol Res. 2015;14(3):8725–8732.
   PubMed Web of Science ®Google Scholar
• Naviaux RK. Metabolic features of the cell danger response. Mitochondrion. 2014;16:7–17.
   PubMed Web of Science ®Google Scholar
• Naviaux J, Schuchbauer M, Li K, et al. Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry. 2014;4(6):e400.
   PubMed Web of Science ®Google Scholar
• Naviaux RK, Zolkipli Z, Wang L, et al. Antipurinergic therapy corrects the autism-like features in the poly (IC) mouse model. PloS One. 2013;8(3):e57380.
   PubMed Web of Science ®Google Scholar
• Naviaux RK, Curtis B, Li K, et al. Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol. 2017;4(7):491–505.
   PubMed Web of Science ®Google Scholar
• Atkuri KR, Mantovani JJ, Herzenberg LA, et al. N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7(4):355–359.
   PubMed Web of Science ®Google Scholar
• Baker DA, Xi Z-X, Shen H, et al. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci. 2002;22(20):9134–9141.
   PubMed Web of Science ®Google Scholar
• Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956–961.
   PubMed Web of Science ®Google Scholar
• Dean OM, Gray KM, Villagonzalo K-A, et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Aust N Z J Psychiatry. 2017;51(3):241–249.
   PubMed Web of Science ®Google Scholar
• Wink LK, Adams R, Wang Z, et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 2016;7(1):26.
   PubMed Web of Science ®Google Scholar
• Keim SA, Gracious B, Boone KM, et al. ω-3 and ω-6 fatty acid supplementation may reduce autism symptoms based on parent report in preterm toddlers. J Nutr. 2018;148(2):227–235.
   PubMed Web of Science ®Google Scholar
• Sheppard KW, Boone KM, Gracious B, et al. Effect of omega-3 and-6 supplementation on language in preterm toddlers exhibiting autism spectrum disorder symptoms. J Autism Dev Disord. 2017;47(11):3358–3369.
   PubMed Web of Science ®Google Scholar
• Boone KM, Gracious B, Klebanoff MA, et al. Omega-3 and-6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: a randomized controlled trial. Early Hum Dev. 2017;115:64–70.
   PubMed Web of Science ®Google Scholar
• Ooi Y, Weng S, Jang L, et al. Omega-3 fatty acids in the management of autism spectrum disorders: findings from an open-label pilot study in Singapore. Eur J Clin Nutr. 2015;69(8):969.
   PubMed Web of Science ®Google Scholar
• Parellada M, Llorente C, Calvo R, et al. Randomized trial of omega-3 for autism spectrum disorders: effect on cell membrane composition and behavior. Eur Neuropsychopharmacol. 2017;27(12):1319–1330.
   PubMed Web of Science ®Google Scholar
• Bent S, Hendren RL, Zandi T, et al. Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. J Am Acad Child Adolesc Psychiatry. 2014;53(6):658–666.
   PubMed Web of Science ®Google Scholar
• Bent S, Bertoglio K, Ashwood P, et al. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord. 2011;41(5):545–554.
   PubMed Web of Science ®Google Scholar
• Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Nat Acad Sci. 2014;111(43):15550–15555.
   PubMed Web of Science ®Google Scholar
• Bent S, Lawton B, Warren T, et al. Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. Mol Autism. 2018;9(1):35.
   PubMed Web of Science ®Google Scholar
• Hendren RL, James SJ, Widjaja F, et al. Randomized, placebo-controlled trial of Methyl B12 for children with autism. J Child Adolesc Psychopharmacol. 2016 Nov;26(9):774–783. PubMed PMID: 26889605.
   PubMed Web of Science ®Google Scholar
• Frye RE, Slattery J, Delhey L, et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry. 2018 Feb;23(2):247–256. PubMed PMID: 27752075; PubMed Central PMCID: PMCPMC5794882.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Stigler KA, Corkins MR, et al. Gastrointestinal factors in autistic disorder: a critical review. J Autism Dev Disord. 2005 Dec;35(6):713–727. PubMed PMID: 16267642.
   PubMed Web of Science ®Google Scholar
• Welch MG. Review: secretin is not effective for the treatment of children with autism spectrum disorders. Evid Based Ment Health. 2011 Nov;14(4):104. PubMed PMID: 21954153
   PubMedGoogle Scholar
• Handen BL, Melmed RD, Hansen RL, et al. A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord. 2009 May;39(5):796–805. PubMed PMID: 19148734.
   PubMed Web of Science ®Google Scholar
• Kang DW, Adams JB, Gregory AC, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017 Jan 23;5(1):10. PubMed PMID: 28122648; PubMed Central PMCID: PMCPMC5264285.
   PubMed Web of Science ®Google Scholar
• Zamzow RM, Ferguson BJ, Stichter JP, et al. Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study. Psychopharmacology (Berl). 2016 Apr;233(7):1171–1178. PubMed PMID: 26762378.
   PubMed Web of Science ®Google Scholar
• Bethea TC, Sikich L. Early pharmacological treatment of autism: a rationale for developmental treatment. Biol Psychiatry. 2007;61(4):521–537.
   PubMed Web of Science ®Google Scholar
• Corsello CM. Early intervention in autism. Infants Young Children. 2005;18(2):74–85.
   Web of Science ®Google Scholar
• Esbensen AJ, Greenberg JS, Seltzer MM, et al. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord. 2009;39(9):1339–1349.
   PubMed Web of Science ®Google Scholar